Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Definitions

• the present invention relates to an oral application unit containing the active substances tramadol and diciofenac and / or their respective physiologically tolerable salts, the two active substances being present in separately formulated subunits in the same application unit.
• Tramadol is an analgesic for the treatment of severe and moderate pain, the principle of which is not based on a pure opioid mechanism. Tramadol also does not show the side effects characteristic of an opioid. In some cases, nausea is observed as an undesirable side effect. Also known, non-opioid analgesics suitable for combating less intense pain are steroid-free pain relievers such as diclofenac-Na, acetylsalicylic acid or ibuprofen
• the WHO recommends combining opioid painkillers with non-steroidal painkillers in order to achieve more effective pain relief and, if necessary, to reduce the amounts required
• European patent EP -B- 0 546 676 teaches that the combination of tramadol-HCl with steroid-free anti-inflammatory agents such as ibuprofen in a composition of 1 1 to 1 200 leads to a synergistically enhanced analgesic effect leads to tramadol-HCl and diclofenac -Na, however, form a sparingly soluble compound. It can be expected that the bioavailability of the two active substances will be reduced and higher doses will be necessary to compensate
• the object of the present invention was therefore to combine the two active substances tramadol and diciofenac or their respective physiologically acceptable salts in a common app cation unit without
• the release profiles of both active substances can be impaired and the bioavailability can be reduced
• this object is achieved by the provision of an oral administration unit which contains the two active substances tramadol and diciofenac and / or their respective physiologically acceptable salts, but the two active substances are each contained in separately formulated subunits in the same administration unit
• the subunits preferably contain as physiologically acceptable salts of tramadol tramadol hydrochloride, tramadol hydrobromide, tramadol sulfate, tramadol phosphate, tramadol fumarate, tramadol succatate, tramadol maleate, Tramadol nitrate, tramadol acetate, tramadol propionate, tramadol malonate, tramadol citrate, tramadol tartrate, tramadol benzoate, tramadol acylate, tramadol phthalate and / or tramadol nicotinate.
• the subunits particularly preferably contain tramadol hydrochloride
• the subunits preferably contain, as physiologically acceptable salts of diclofenac, diclofenac-sodium, diclofenac-potassium, diclofenac-calcium, diclofenac-magnesium and / or diclofenac-colestyramine.
• the subunits particularly preferably contain diclofenac-sodium
• the oral administration unit preferably contains the active substances tramadol and diciofenac in a ratio of c ⁇ 4 to 4 ⁇ -1, particularly preferably in a ratio of 0.5 1 to 3 1 and very particularly preferably in a ratio of 1 1 to 2.5 1
• the subunits in the sense of the invention are solid pharmaceutical formulations which, in addition to the respective active ingredient and / or its respective physiologically acceptable salts, contain the customary auxiliaries and additives
• the subunits are preferably in multiparticulate form, such as, for example, microtablets, microcapsules, ion exchange resinates, granules, active substance crystals or pellets.
• the subunits are particularly preferably in the form of granules, active substance crystals or pellets.
• the form of the subunits particularly preferably comprises by extrusion and / or or spheronization-produced pellets or build-up pellets
• the oral administration unit can also contain at least one of the two active substances in a delayed, optionally multiparticulate form, preferably both active substances in a delayed, optionally multiparticulate form
• the oral administration unit can also contain at least one of the active substances in the non-retarded form Achieve pain change and the slow release from the retarded form enables the maintenance of therapeutic blood levels over a longer period of time.
• the release of the active ingredients will be particularly preferably adjusted so that the oral administration unit has to be administered at most twice, preferably only once a day Analgesics known in which mixture ratios they are to be used so that the desired effect is achieved
• the release profile of the oral administration units is preferably to be controlled in such a way that the tramadol or the diciofenac is released within 8 hours if used twice a day within 8 hours> 70% or> 60% by weight
• the invention therefore also relates to oral administration units for a double application per Day, which are characterized in that the tramadol or the diciofenac is released within 8 hours> 70% or> 60% by weight
• the release profile should preferably be controlled so that the tramadol or the diciofenac> 70 within 16 hours
• Another object of the invention is therefore also oral administration units for a single application per day, which are characterized in that
• the retardation of the respective active substances in the respective subunits can preferably take place by means of a retarding coating, fixing to an ion exchange resin, embedding in a retarding matrix or a combination thereof b
• Suitable retarding coatings include water-insoluble waxes or polymers, such as, for example, acrylic resins, preferably poly (meth) acrylates, or water-insoluble celluloses, preferably ethyl cellulose. These materials are from the prior art, for example Bauer , Lehmann, Osterwald, Rothgang
• the sustained release coatings can also be non-retarding, preferably water-soluble polymers, preferably in amounts of up to 30% by weight, such as polyvinylpyrrohdon or water-soluble celluloses, preferably hydroxypropylmethyl cellulose or hydroxypropyl cellulose, and / or hydrophilic pore formers, such as sucrose or sodium chloride Mannitol and / or the known plasticizers contain
• the multiparticulate subunits can also have further coatings. Coatings can also be present which dissolve depending on the pH. In this way, it can be achieved that the subunits pass through the gastric tract undissolved and only release in the intestinal tract. Coatings can also be used serve to improve the taste
• Another common procedure for retardation is the fixation of the active ingredients to ion exchange resins.
• diciofenac preferably colestyramine is used as the anionic ion exchange resin.
• polystyrene sulfonates are preferably used as the cationic ion exchange resin
• the subunits of the active substances can also be present in a retarding matrix, preferably uniformly distributed.
• Physiologically compatible, hydrophilic materials which are known to the person skilled in the art can be used as matrix materials.
• Preferred hydrophilic matrix materials are polymers, particularly preferably cellulose ethers, cellulose esters and / or acrylic resins be very particularly preferred as matrix materials ethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxymethyl cellulose poly (meth) acrylic acid and / or their derivatives, such as their salts, amides or esters
• hydrophobic materials such as hydrophobic polymers, waxes, fats, long-chain fatty acids, fatty alcohols or corresponding esters or ethers, or mixtures thereof.
• Mono- or diglycides of C 2 -C 30 fatty acids and / or C are particularly preferred as hydrophobic materials
• the dosage form of the oral administration unit according to the invention is preferably a sachet, a capsule or a tablet, particularly preferably a capsule or a tablet.
• the tablet is preferably a pellet tablet which particularly preferably disintegrates quickly
• the tablet can disintegrate again into the subunits upon contact with aqueous media and release the active substances spatially separated from one another.
• Crospovidones, croscarmelose, strong and / or low-substituted hydroxypropyl cellulose can be used as disintegrants, which separate the subunits upon contact with aqueous media
• the administration unit according to the invention preferably has at least one notch as a tablet, which enables the dose to be divided, preferably halved. This enables adaptation to the individual needs of the patient, in accordance with the amount of analgesics to be administered individually
• the multiparticulate subunits and the oral administration unit according to the invention can be produced by the various methods known to the person skilled in the art. These methods are known from the prior art, eg "Pharmaceutical Pelletization Technology", Drugs and the Pharmaceutical Sciences Vol 37, publisher Marcel Dekker, known. They are hereby introduced as a reference. If the oral administration unit according to the invention, such as the tablet, has coatings, these can be sprayed on using customary methods, such as, for example, dragging of solutions, melts, dispersions or suspensions, by melting processes or by powder application processes
• the oral administration unit according to the invention can have at least one further coating.
• Such a coating can dissolve, for example, depending on the pH. In this way, the oral administration unit can be achieved The gastrointestinal tract passes undissolved and is only released in the intestinal tract
• the preparations were either in a rotating basket apparatus (Examples 1 and 3) or in a leaf stirrer apparatus (Examples 2 and 4) according to the European Pharmacopoeia at a temperature of 37 ° C. and a rotation speed of 100 mm 1 (Examples 1 and 3) or 50 mm 1 (Examples 2 and 4) placed in 600 ml of artificial gastric juice without enzymes (pH 1, 2) for 2 hours. The preparations were then placed in 900 ml of artificial intestinal juice without enzymes (pH 7.2) for a further 8 (example 3). This pH was maintained until the investigation. The amount of the respective active ingredient tramadol or diciofenac released at a given time was determined by HPLC. The values and curves shown are the mean values from 6 samples in each case
• Tramadol pellets with an active ingredient content of 55% by weight were produced by aqueous granulation with microcrystalline cellulose and low-substituted hydroxypropyl cellulose and subsequent extrusion / spheronization.
• the pellets with a size of 800-1250 ⁇ m are dried and then first in the fluidized bed at a supply air temperature of 60 ° C.
• the film thicknesses are given in percent by weight based on the starting weight of the pellets or the pellets with subcoat
• the diclofenac pellets with an active substance content of 37% by weight were produced by aqueous granulation with microcrystalline cellulose and lactose monohydrate and subsequent extrusion / spheronization.
• the pellets with a size of 800-1250 ⁇ m were dried and then first in the fluidized bed at a supply air temperature of 60 ° C. 1% by weight of hydroxypropylmethyl cellulose as a subcoat and then filmed with 13% by weight of Surelease E-7-7050 as a retard coating.
• the film orders are given in percent by weight based on the starting weight of the pellets or the pellets with subcoat.
• the Diciofenac retard pellets are then dried and dried in an oven annealed at 60 ° C for 2 hours
• Microcrystalline cellulose (Avicel PH 105 from FMC) 31.4 mg
• Microcrystalline cellulose (Avicel PH 105 from FMC) 75.0 mg
• the release profile was as follows and is shown in Fig 1
• Fig. 2 shows the release profile of a matrix tablet with a diameter of 12 mm, which contains 75 mg tramadol-HCl and 50 mg diclofenac-Na in a common hydrophilic matrix made of hydroxypropylmethyl cellulose.
• a comparison of Fig. 1 with Fig. 2 shows that the amount released of the active ingredients Tramadol and Diciofenac from the oral administration unit according to the invention after 8 hours is significantly greater than the release from the so-called common matrix tablets
• Fig. 3 shows the release of diciofenac from diciofenac retard pellets, which are filmed with a 1% by weight subcoat of hydroxypropylmethyl cellulose (Opadry OY 29020, analogous to Example 1) and a 13% by weight surelease 7-7050 coating.
• Fig. 4 shows the release of tramadol from tramadol retard pellets with a 3% by weight subcoat of hydroxypropylmethyl cellulose (Opadry OY 29020, analogous to Example 1) and talc and a 1 1% by weight surelease 7-7050 coating
• FIG. 1 A comparison of Fig. 1 with Figs. 3 and 4 shows that the amounts released and the release profiles of tramadol and diciofenac from the oral administration units according to the invention correspond to the amounts and release profiles from the forms containing only tramadol or only diclofenac
• Tramadol retard pellets and Diciofenac retard pellets were produced analogously to Example 1
• Tramadol initial dose pellets were produced analogously to the retarded tramadol pellets, but not with the Surelease E-7-7050 coating but only filmed with 3% subcoat from Opadry OY 29020 clear and talc.
• the three Types of pellets were mixed together in a Bohle container mixer for 10 minutes
• pellets corresponding to a dose of 100 mg of tramadol hydrochloride and 50 mg of diclofenac-Na, were mixed first with 30 mg of crospovidone and then with 330.6 mg of cellactose and 7.4 mg of magnesium stearate, and into 7 x 14 mm tablets with a score line and one Weight of 736 mg pressed This disintegrates again into the individual pellets in a water medium
• Microcrystalline cellulose (Avicel PH 105 from FMC) 31.4 mg
• Microcrystalline cellulose (Avicel PH 105 from FMC) 10.5 mg
• Microcrystalline cellulose (Avicel PH 105 from FMC) 75.0 mg
• Crospovidone (Kollidon CL from BASF) 30 mg
• the release profile was as follows
• Tramadol pellets with an active ingredient content of 55% by weight were produced by aqueous granulation with microcrystalline cellulose and low-substituted hydroxypropyl cellulose and subsequent extrusion / spheronization.
• the pellets with a size of 800-1250 ⁇ m were dried and then in the fluidized bed at a supply air temperature of 60 ° C. 15% by weight retard coating, based on the starting weight of the pellets, was filmed.
• the dried Tramadol retard pellets were then dried in a drying cabinet at 60 ° C. for a further 2 h to adjust the release profile before they were coated with an overcoat of 0.6% by weight hydroxypropylmethyl cellulose the starting weight of the pellets with slow release coating were coated.
• the diclofenac pellets with an active ingredient content of 37% by weight are produced by aqueous granulation with microcrystalline cellulose and lactose monohydrate and subsequent extrusion / spheronization.
• the dried pellets with a The sizes from 800 to 1250 ⁇ m were then filmed in the fluidized bed at 60 ° C. supply air temperature with 16% by weight retard coating, based on the starting weight of the pellets.
• the dried diciofenac retard pellets were then heat-treated in a drying cabinet at 60 ° C.
• Microcrystalline cellulose (Avicel PH 105) 42.0 mg of low substituted hydroxypropyl cellulose (l-HPC LH 40.0 mg
• Microcrystalline cellulose (Avicel PH 105) 75.0 mg
• the release profile was as follows
• Tramadol hydrochloride and microcrystalline cellulose were granulated with a water solution of Povidon K30, dried, sieved and, after mixing with magnesium stearate, pressed into microtablets with a weight of 15.0 mg and a diameter of 3 mm
• micro-tablets were first coated at 60 ° C supply air temperature with 2% by weight subcoat of Opadry OY 29020 clear, based on the weight of the tablet cores, and then with 8% by weight retard coating, based on the weight of the tablets with subcoat, the final weight of the micro-tablet is 16 , 6 mg
• composition of a Tramadol retard micro tablet Composition of a Tramadol retard micro tablet
• Microcrystalline cellulose (Avicel PH 101 of 4.0 mg
• Diciofenac tablets were produced analogously to the Tramadol microtablets and also compressed into microtablets with a weight of 15 mg and a diameter of 3 mm.
• the microtablets are coated with an enteric coating of 8% polyacrylate dispersion
• composition of an enteric-coated Diciofenac micro tablet D ⁇ clofenac-Na 10.0 mg
• Microcrystalline cellulose (Avicel PH 101 of 4.0 mg
• the release profile was as follows

Landscapes

• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pain & Pain Management (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Rheumatology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (2)

Family

ID=7911586

Family Applications (1)

Country Status (15)

Cited By (1)

Families Citing this family (23)

Family Cites Families (5)

• 1999
  • 1999-06-17 DE DE19927689A patent/DE19927689A1/de not_active Ceased
• 2000
  • 2000-06-13 PT PT00942052T patent/PT1185253E/pt unknown
  • 2000-06-13 ES ES00942052T patent/ES2215680T3/es not_active Expired - Lifetime
  • 2000-06-13 WO PCT/EP2000/005386 patent/WO2000078294A2/de not_active Ceased
  • 2000-06-13 MX MXPA01013046A patent/MXPA01013046A/es active IP Right Grant
  • 2000-06-13 JP JP2001504359A patent/JP4889897B2/ja not_active Expired - Fee Related
  • 2000-06-13 DK DK00942052T patent/DK1185253T3/da active
  • 2000-06-13 CA CA002377174A patent/CA2377174C/en not_active Expired - Fee Related
  • 2000-06-13 AT AT00942052T patent/ATE260650T1/de active
  • 2000-06-13 NZ NZ516593A patent/NZ516593A/en not_active IP Right Cessation
  • 2000-06-13 DE DE50005529T patent/DE50005529D1/de not_active Expired - Lifetime
  • 2000-06-13 EP EP00942052A patent/EP1185253B1/de not_active Expired - Lifetime
  • 2000-06-13 AU AU56805/00A patent/AU778151B2/en not_active Ceased
  • 2000-06-13 HU HU0201687A patent/HUP0201687A3/hu unknown
  • 2000-06-13 HK HK02106641.8A patent/HK1045113A1/zh unknown
• 2001
  • 2001-12-17 US US10/016,130 patent/US20020156133A1/en not_active Abandoned

Also Published As

Similar Documents

Legal Events